Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial

Isaac Weber, Caterina Zagona-Prizio, Torunn E. Sivesind, Madeline Adelman, Mindy D. Szeto, Ying Liu, Stefan H. Sillau, Jacquelyn Bainbridge, Jost Klawitter, Cristina Sempio, Cory A. Dunnick, Maureen A. Leehey, Robert P. Dellavalle

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Seborrheic dermatitis (SD) affects 18.6%-59% of persons with Parkinson disease (PD), and recent studies provide evidence that oral cannabidiol (CBD) therapy could reduce sebum production in addition to improving motor and psychiatric symptoms in PD. Therefore, oral CBD could be useful for improving symptoms of both commonly co-occurring conditions. Objective: This study investigates whether oral CBD therapy is associated with a decrease in SD severity in PD. Methods: Facial photographs were collected as a component of a randomized (1:1 CBD vs placebo), parallel, double-blind, placebo-controlled trial assessing the efficacy of a short-term 2.5 mg per kg per day oral sesame solution CBD-rich cannabis extract (formulated to 100 mg/mL CBD and 3.3 mg/mL THC) for reducing motor symptoms in PD. Participants took 1.25 mg per kg per day each morning for 4 ±1 days and then twice daily for 10 ±4 days. Reviewers analyzed the photographs independently and provided a severity ranking based on the Seborrheic Dermatitis Area and Severity Index (SEDASI) scale. Baseline demographic and disease characteristics, as well as posttreatment SEDASI averages and the presence of SD, were analyzed with 2-tailed t tests and Pearson χ2 tests. SEDASI was analyzed with longitudinal regression, and SD was analyzed with generalized estimating equations. Results: A total of 27 participants received a placebo and 26 received CBD for 16 days. SD severity was low in both groups at baseline, and there was no treatment effect. The risk ratio for patients receiving CBD, post versus pre, was 0.69 (95% CI 0.41-1.18; P=.15), compared to 1.20 (95% CI 0.88-1.65; P=.26) for the patients receiving the placebo. The within-group pre-post change was not statistically significant for either group, but they differed from each other (P=.07) because there was an estimated improvement for the CBD group and an estimated worsening for the placebo group. Conclusions: This study does not provide solid evidence that oral CBD therapy reduces the presence of SD among patients with PD. While this study was sufficiently powered to detect the primary outcome (efficacy of CBD on PD motor symptoms), it was underpowered for the secondary outcomes of detecting changes in the presence and severity of SD. Multiple mechanisms exist through which CBD can exert beneficial effects on SD pathogenesis. Larger studies, including participants with increased disease severity and longer treatment periods, may better elucidate treatment effects and are needed to determine CBD’s true efficacy for affecting SD severity.

Original languageEnglish (US)
Article numbere49965
JournalJMIR Dermatology
Volume7
DOIs
StatePublished - 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 JMIR Publications Inc.. All rights reserved.

Keywords

  • cannabidiol
  • cannabis
  • cannabis
  • CBD
  • CBD treatment
  • chi-square
  • clinical trial
  • clinical trials
  • controlled trial
  • dermatitis
  • dermatology
  • drug
  • drug response
  • image
  • imaging
  • outcome
  • Parkinson
  • Parkinson disease
  • photograph
  • photographs
  • randomized
  • RCT
  • seborrheic dermatitis
  • seborrheic dermatitis
  • sebum
  • SEDASI
  • skin
  • treatment

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this